Afatinib/bevacizumabAcquired resistance: 8 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2018年 / 1726卷 / 1期

关键词：

D O I：

10.1007/s40278-018-53659-z

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：20 / 20

相关论文

共 50 条

[21] Afatinib/ErlotinibLack of efficacy: 2 case reports
Reactions Weekly, 2024, 2032 (1) : 22 - 22
[22] Afatinib/cetuximabAcquired resistance: case report
Reactions Weekly, 2018, 1727 (1) : 20 - 20
[23] Afatinib/gefitinibAcquired resistance: case report
Reactions Weekly, 2023, 1942 (1) : 18 - 18
[24] Afatinib/erlotinibDevelopment of afatinib and erlotinib resistance in lung adenocarcinoma: case report
Reactions Weekly, 2018, 1726 (1) : 21 - 21
[25] Afatinib/gefitinibDevelopment of resistance to gefitinib and afatinib in lung adenocarcinoma: case report
Reactions Weekly, 2019, 1771 (1) : 21 - 21
[26] Afatinib/trastuzumab-emtansineVarious toxicities and resistance to afatinib: case report
Reactions Weekly, 2020, 1835 (1) : 18 - 18
[27] Eptacog-αDevelopment of resistance: 8 case reports
Reactions Weekly, 2019, 1781 (1) : 159 - 159
[28] Anastrozole/exemestane/letrozoleDrug resistance: 8 case reports
Reactions Weekly, 2020, 1794 (1) : 27 - 27
[29] AntineoplasticsDevelopment of resistance in metastatic melanoma: 8 case reports
Reactions Weekly, 2017, 1639 (1) : 38 - 38
[30] Afatinib/cisplatin/pemetrexedNausea, vomiting and development of resistance to afatinib: case report
Reactions Weekly, 2019, 1737 (1) : 17 - 17

← 1 2 3 4 5 →